Research

Time-related improvement of survival in resectable gastric cancer: the role of Japanese-style gastrectomy with D2 lymphadenectomy and adjuvant chemotherapy

Juan J Grau*1, Ramon Palmero1, Maribel Marmol1, Jose Domingo-Domenech1, Mariano Monzo1, Jose Fuster2, Oscar Vidal2, Constantino Fondevila2 and Juan C Garcia-Valdecasas2

Address: 1Oncology Department, ICMHO (Institut Clinic de Malalties Hemato-Oncologiques) and IDIBAPS (Instituto de Investigaciones Biomédicas Augusto Pi Sunyer); University of Barcelona. Hospital Clinic, Barcelona, Spain and 2Gastrointestinal Surgery Depart. University of Barcelona. Hospital Clinic, Barcelona, Spain

Email: Juan J Grau* - jjgrau@clinic.ub.es; Ramon Palmero - 36038rps@comb.es; Maribel Marmol - rmarmel@yahoo.es; Jose Domingo-Domenech - 33884jdd@comb.es; Mariano Monzo - mmmonzo@ub.edu; Jose Fuster - jfuster@clinic.ub.es; Oscar Vidal - 32162ovp@clinic.ub.es; Constantino Fondevila - cfonde@clinic.ub.es; Juan C Garcia-Valdecasas - jcvale@clinic.ub.es

* Corresponding author

Abstract

Background: We investigated the change of prognosis in resected gastric cancer (RGC) patients and the role of radical surgery and adjuvant chemotherapy.

Methods: We retrospectively analyze the outcome of 426 consecutive patients from 1975 to 2002, divided into 2 time-periods (TP) cohort: Before 1990 (TP1, n = 207) and 1990 or after (TP2; n= 219). Partial gastrectomy and D1-lymphadenectomy was predominant in TP1 and total gastrectomy with D2-lymphadenectomy it was in TP2. Adjuvant chemotherapy consisted of mitomycin C (MMC), 10–20 mg/m2 iv 4 courses or MMC plus Tegafur 500 mg/m2 for 6 months.

Results: Positive nodes were similar in TP2/TP1 patients with 56%/59% respectively. Total gastrectomy was done in 56%/45% of TP2/TP1 respectively. Two-drug adjuvant chemotherapy was administered in 65%/18% of TP2/TP1 respectively. Survival at 5 years was 66% for TP2 versus 42% for TP1 patients (p < 0.0001). Survival by stages II, IIIA y IIIB for TP2 versus TP1 patients was 70 vs. 51% (p = 0.0132); 57 vs. 22% (p = 0.0008) y 30 vs. 15% (p = 0.2315) respectively. Multivariate analysis showed that age, stage of disease and period of treatment were independent variables.

Conclusion: The global prognosis and that of some stages have improved in recent years with case RGC patients treated with surgery and adjuvant chemotherapy.

Background

For many authors, gastric carcinoma remains one of the leading causes of cancer death worldwide, second only to lung carcinoma [1,2]. Five-year relative survival of patients from European countries ranges from 10 to 30% [3,4], similar to that reported in USA (15 to 28%) [5]. Local and regional gastric carcinoma showed a 5-year relative survival of 55–59% and 20–22% respectively [6]. In
this latter subgroup of patients the surgical treatment of choice consisted of gastrectomy combined with regional lymph node dissection. The relevance of radical surgery, extending lymph node dissection as wide as possible has been highlighted. The experience of an expert surgeon has been shown to improve clinical outcome in some tumors [7]. In the statistical outcome of two European trials, one from the United Kingdom and the other, The Netherlands, comparing D1 versus D2 lymphadenectomy a survival rate of approximately 20% for D1 group was assumed [8,9]. This 20% overall survival was based on historic data from both those countries. Nevertheless, the overall 5-year survival for D1 group jumped to 34% and 45% respectively, without any dramatic change in T classification distribution, suggesting that the results from expert surgeons may improve final cure rates [10,5].

In spite of surgical treatment, thousands of loco-regional gastric cancer patients relapse and die worldwide each year. Taking into account the poor survival of gastric carcinoma after treatment only with surgery, several adjuvant strategies have been developed in recent years to reduce relapse rates and to improve long-term survival. Survival rates of up to 40% in selected patients receiving postoperative adjuvant chemoradiation has been obtained after curative resection (R0) in contrast to 30% survival if patients were treated with surgery alone [11]. Japanese authors have proposed that improvement in survival can be also achieved with surgery plus adjuvant chemotherapy based on mitomycin and fluorouracil derivates [12], thus avoiding toxic effects through radiotherapy. Likewise, our group reported a 60% 5-year survival among patients with loco-regional gastric carcinoma treated with gastrectomy followed by 6 months of chemotherapy based on mitomycin-C and tegafur (a 5-fluorouracil pro-drug) without radiotherapy [13,14].

Our prospectively maintained database contains data on patients with early and locally advanced gastric carcinoma treated with surgery since 1975. After 1990 the principal surgical option was D2 dissection plus gastrectomy. Initially, patients who achieved disease-free status after surgery were offered the option of adjuvant chemotherapy within a clinical trial or follow-up with no further therapy. After 1990, we offered adjuvant chemotherapy to all patients. In order to evaluate the improvement in the prognosis among operated gastric cancer patients, we have retrospectively compared the long-term therapeutic results of patients diagnosed and treated at our institution before and after 1990.

In this study, we analyzed the outcome and survival of resected non-metastatic gastric cancer patients over this time period, comparing the periods before and after 1990 when Japanese-style surgery followed by adjuvant chemo-therapy were included as the preferable treatment option for the majority of patients.

**Patients and methods**

This retrospective study includes 426 consecutive non-metastatic patients who underwent primary surgery for gastric adenocarcinoma with curative R0 intent (stages Ia to IV M0).

Since 1975, patients with early or locally advanced gastric adenocarcinoma have been operated with subtotal or total gastrectomy according to the location and the size of the primary tumor. The range of lymph node resection was performed following the classification and rules of the Japanese Research Society for the Study of Gastric Cancer [15]. D1 resections were performed until 1990 when, after a 6-months training program in Japan, surgeons standardized the use of the more extended D2 dissection at our institution. Resections of spleen and tail of pancreas were performed in proximal gastric tumors to achieve adequate removal of D2 lymph node stations 10 and 11.

Each patient was staged according to the tumor-node-metastasis system valid at the time of surgery. Recently, the database has been updated and patients diagnosed before 1997 were re-staged according to the latest guidelines of the AJCC published in 1997 [16].

**Adjuvant chemotherapy**

From 1975 to 1990, patients after complete resection of gastric cancer were offered adjuvant chemotherapy treatment within clinical trials or they were followed up without treatment. Since 1990, adjuvant chemotherapy has been offered to all patients, both within and outside the framework of clinical trials. Two different chemotherapy schedules were used: Mitomycin-C (MMC) 10–20 mg/m2 i.v. bolus once every 6 weeks, or MMC plus Tegafur (TG) 500 mg/m2 p.o. daily. Both regimens were administered during 6 months after surgery. After 1995, MMC-TG was routinely to all patients out of clinical trials. After adjuvant treatment, all patients were followed up with clinical checking, biochemical blood test, including tumor makers (CEA and CA 19.9), chest X-ray film, and liver ultrasonography every 3 to 6 months for five years and yearly thereafter. Other explorations such as CT-scan or endoscopy were performed if clinical or complementary test alterations appeared.

**Statistical analysis**

Follow-up and survival data were recorded according to the rules set down by Peto et al [17]. The database was last updated on 30 November 2004. In this study, data were retrospective analyzed. For statistical analysis the SPSS program (version 11.0, SPSS Inc, Chicago) was used. Comparison between groups based on patient's character-
istics was performed using the $\chi^2$ test for discrete data and t-test for continuous data, both two-tailed. Patients were divided firstly in two groups, depending on the time period (TP) in which they received treatment i.e. TP1 = 1975–1989, and TP2 = 1990–2002. Secondly, global survival of all patients was divided in five-year period). Survival probabilities were estimated by the Kaplan-Meier product-limit method [18] and the log-rank test was used to evaluate the difference between survival curves [19]. A p-value of 0.05 was considered to be the limit of significance for all analysis.

Cox's proportional hazard model with covariates for main prognostic factors like gender, positive lymph nodes, adjuvant chemotherapy and period of treatment was applied.

**Results**

Patient characteristics are outlined in Table 1. In the TP1, 207 patients were included in the study as they were diagnosed and treated for primary gastric cancer, while in TP2, the patients included with the same criteria were 219. There were no significant differences in gender distribution, with a male/female ratio of 2:1. Patients TP2 were older than the TP1 (>61 years: 46% vs. 68%; $p = 0.001$). Distribution of tumor location was well balanced. The proportion of T1/T2 tumors in TP2 patients was higher compared with those TP1 patients (35% versus 21%, $p < 0.001$). There were no differences between the two groups in the proportion of node positive/negative staging, (56.1%/43.8% in TP2 patients and 58.9%/41.1% in TP1 patients). Because the staging rules, node positive N3 tumors were observed in 9 out of 219 (4%) (TP2 patients versus none in TP1 patients). In spite of these differences, a similar distribution of stages was seen in both groups, stage I plus II/stage III plus IV in TP2 patients (50.2%/49.8) compared with those TP1 patients (47.4%/52.6%)($p = 0.562$).

**Table 1: Patient's demographics and tumors characteristics**

| Year of diagnostic | Before 1990 (n = 207) | 1990 and after (n = 219) |
|-------------------|-----------------------|-------------------------|
|                   | Total                 | %                       | %          | n | n | p     |
| Gender            |                       |                        |            |   |    |       |
| Male              | 276                   | 64.9                   | 64.4       | 135| 141| .919  |
| Female            | 150                   | 35.1                   | 35.6       | 72 | 78 |       |
| Age. years        |                       |                        |            |   |    | <.001 |
| < 61              | 182                   | 54.1                   | 31.7       | 112| 70 |       |
| > 61              | 244                   | 45.9                   | 68.3       | 95 | 149|       |
| Tumor location*   |                       |                        |            |   |    | .097  |
| Cardia            | 32                    | 6.3                    | 11.6       | 10 | 22 |       |
| Body              | 130                   | 37.3                   | 36.5       | 61 | 69 |       |
| Antrum            | 187                   | 56.3                   | 51.9       | 89 | 98 |       |
| Local invasion**  |                       |                        |            |   |    | <.001 |
| T1                | 44                    | 2.9                    | 17.4       | 6  | 38 |       |
| T2                | 76                    | 17.9                   | 17.8       | 37 | 39 |       |
| T3                | 294                   | 78.7                   | 59.7       | 163| 131|       |
| T4                | 12                    | 0.5                    | 5.1        | 1  | 11 |       |
| Lymph node involvement*** |       |                        |            |   |    | .624  |
| N0                | 181                   | 41.1                   | 43.8       | 85 | 96 |       |
| N1                | 141                   | 36.2                   | 30.1       | 75 | 66 |       |
| N2                | 95                    | 22.7                   | 21.9       | 47 | 48 |       |
| N3                | 9                     | 0.0                    | 4.1        | 0  | 9  |       |
| Stage****         |                       |                        |            |   |    | .562  |
| IA                | 34                    | 0.5                    | 15.0       | 1  | 33 |       |
| IB                | 58                    | 15.5                   | 11.9       | 32 | 26 |       |
| II                | 116                   | 31.4                   | 23.3       | 65 | 51 |       |
| IIIA              | 118                   | 30.9                   | 24.7       | 64 | 54 |       |
| IIIB              | 83                    | 21.3                   | 17.8       | 44 | 39 |       |
| IV                | 17                    | 0.5                    | 7.3        | 1  | 16 |       |

* : Not specified in 77 patients (47 in PT1 and 30 in PT2)


**Surgery**

Treatment characteristics are shown in Table 2. All patients underwent subtotal or total gastrectomy: 44%/56% for TP2 patients, and 55%/45% for TP1 patients respectively. Twenty-nine splenectomies were performed, four of them with subtotal gastrectomy and twenty-five with total gastrectomy. More extended lymph node dissections were performed among the TP2 patients compared with those PT1 patients (D2 65% vs. 10%, respectively).

Perioperative mortality in TP2 patients was 4% (9 out of 219), mainly by sepsis or pulmonary thromboembolism, and 1% (2 out of 207) (p = 0.091) in TP1 patients.

Forty-five percent of the patients received no adjuvant treatment after surgery, followed by clinical checking until progression or death. No difference was observed in the rate of patients that received no adjuvant chemotherapy between both TP2/TP1 periods (42.7% versus 47.3%; p = .436). Among those patients who received adjuvant chemotherapy, the MMC-TG combination was the most frequently prescribed regimen in TP2 patients (65%) compared with MMC alone, the most commonly used treatment in TP1 patients (82%).

**Survival analysis**

Median follow-up for all patients was 216 months. At the time of analysis, the 219 TP2 patients had a median follow up of 96 months, whereas the 207 TP1 patients had been followed-up for a median of 260 months. Median survival was 120+ months (median not reached) and 32.31 months for each period, respectively. 5-year overall survival was 66% for TP2 patients versus 42% for TP1 patients (p < 0.0001). Figure 1 shows a Kaplan-Meier survival curves with plateau beginning in 5th year in both groups, and maintains this line for more than 10 years.

**Staging**

When subgroups analysis was done according to the staging, the significant improvement in survival seems to be restricted to stages II and IIIA, with an insignificant improvement at stage IIIB (see table 3). Five-year overall survival at stages II, IIIA and IIIB for each TP2/TP1 period was 70% vs. 51% (p = 0.0132), 57 vs. 23% (p = 0.0008) and 30 vs. 15% (p = 0.2315), respectively (Figure 2). Both node negative and positive patients show better survival in TP2 patients compared with those treated before 1990 (5-year overall survival: 73% versus 62%, p = 0.0328 and 53 versus 23%, p < 0.0001) (Figure 3). An improvement in survival has been observed in D2 lymphadenectomy patients comparing TP2 with TP1 (5-year overall survival: 66% versus 42%, p = 0.0076) as patients treated with adjuvant chemotherapy as patients non treated with adjuvant chemotherapy.

**Survival and adjuvant chemotherapy**

When comparing the outcome of patients treated with adjuvant chemotherapy using MMC only with those patients treated with adjuvant MMC-TG during period TP2, a better global survival was observed in patients treated with the two-drug regimen. Global survival at 5 years for those treated with adjuvant MMC was 58% for TP2 patients, and 47% for those TP1 patients but these differences were not statistically significant (p = 0.2346.) Nevertheless, for those TP2 patients treated with adjuvant

---

**Table 2: Surgical Treatment and Adjuvant Chemotherapy Details**

|                      | Year of diagnostic |               |               |               | p      |
|----------------------|--------------------|---------------|---------------|---------------|--------|
|                      | Before 1990        | 1990 and after|
|                      | Total              | %             | n             | %             | n      |
| Gastrectomy          |                    |               |               |               |        |
| Subtotal             | 168                | 55.3          | 83            | 44.3          | 85     |
| Total                | 175                | 44.7          | 68            | 55.7          | 107    |
| Splenectomy*         | 29                 | 3.4           | 5             | 12.5          | 24     |
| Lymphadenectomy**    |                    |               |               |               |        |
| D1                   | 249                | 89.3          | 184           | 34.6          | 65     |
| D2                   | 145                | 10.7          | 22            | 65.4          | 123    |
| Adjuvant Chemotherapy|                    |               |               |               |        |
| No                   | 192                | 47.3          | 98            | 42.7          | 94     |
| Yes                  | 235                | 52.7          | 109           | 57.3          | 126    |
| Chemotherapy schedule|                    |               |               |               |        |
| MMC                  | 133                | 81.7          | 89            | 34.9          | 44     |
| MMC-TG               | 102                | 18.3          | 20            | 65.1          | 82     |

*; Not specified in 54 patients (47 in PT1 and 30 in PT2)

**; Not specified in 32 patients (31 in PT1 and 1 in PT2)
MMC-TG, survival at 5 years was 87% while for TP1 patients the rate was 54% (p = 0.0113). MMC-TG was the adjuvant chemotherapy in 44% of the patients after 1995 versus 20% of the patients between 1990 and 1994.

**Timing of treatment**

When we look at the date when patients were diagnosed and treated, if we divided in five-year period, we can see that there is an improvement in survival in patients treated more recently. The best results have been mainly observed in patients treated after 1995 compared with patients treated earlier with a rate of long-term survivors of 73% and 41% respectively (p < 0.0001).

The 87 patients treated between 1995 and 1999 have an average follow-up of 90 months. Survival at 5 years is 67%. The 55 patients treated since 1990 have a follow-up of 48 months and of these, 9 have died of the disease (16%) and 4 more are alive but have been relapsed (7%) (Figure 4).

The Cox multivariate analysis applied using the significant variables in the univariate analysis showed that stage (p = 0.002) and period (TP2 over TP1) (p < 0.001) of treatment continue to be statistically significant as independent variables. When we analyzed the period of treatment before and after 1995 (instead of 1990) the stage (p = 0.003) and period of treatment (p < 0.001) were also independent variables.

**Discussion**

Gastric cancer can be a fatal disease even in its earliest stages. There is a survival rate of approximately 40% at 5 years in patients with loco-regional disease. These patients would be candidates for procedures such as gastrectomies and lymphadenectomies. Nevertheless, as mentioned before, an improvement in cure rates has been observed in recent years. In some cases this improvement is produced through surgery plus chemotherapy or radiotherapy but in other cases, through expert surgery only. Patients with affected lymph nodes in the postoperative pathological staging have the worst prognosis. In our series, survival at 5 years in patients with positive nodes rose from 23% to 53% on the basis of whether they were treated before or after 1990. These results are superior to those published by Sasako et al [20], which were 30%–40%. This data suggests that since 1990, there has been improved postoperative staging and in contrast, prior to 1990, there may have been patients who were down-staged.

When we compare patients treated after 1990, survival rate at 5 years according with the stages, we can see that our results are similar to those published by Japanese groups and both are better that those published by other Western authors (Table 4).

Our results indicate an improvement in global survival in patients treated after 1990 when D2 dissection and adjuvant chemotherapy was the treatment applied in the majority of patients. However, this improvement in survival is clearer still from 1995 onwards. The reasons for this improvement cannot be explained simply by earlier diagnosis in patients with earlier stage as it occurs in different stages of the disease. Only stage IIIB does not show a significant statistical improvement in the survival curve, probably because of the low number of patients of our series in this situation. Better post-operative care was not the explanation for this improvement, as perioperative mortality was higher in patients treated after 1990 than before, probably due to the greater number of D2 lymphadenectomy carried out. This procedure shows mortality rates higher than those of D0 and D1 dissections in the majority of studies [21]. In addition, the majority of surgical procedures were carried out by the same team of 4 surgeons who have acquired wider experience through the years. There are evidences to show that the surgeon’s learning curve can improve the final results of treatment [22] and partially explain the survival improvement after 1995.

Adjuvant chemotherapy with 2 drugs has shown itself to be superior to that with MMC only [23]. Also, D2 surgery along with chemotherapy with 2 drugs has demonstrated long-term survival rates of up to 75%. All of this data suggested that improved outcomes could be the result of bet-
ter surgery carried out by more experienced surgeons together with adjuvant chemotherapy based on MMC plus Tegafur.

Several factors could produce a time-related bias in the studies focused on temporary improvements in survival of diseases. These include changes in radiological facilities for detection and diagnosis of metastases, changes in diagnostic criteria and evolution of clinical characteristics, allowing a more accurate staging of the patients. Nevertheless, in our study, the radiological facilities used to detect metastases of primary gastric cancer were similar after 1990 and include liver ultrasound, chest X-rays, and abdominal CT scan for confirmation.

One can argue that the improvement is related to poor results in the first cohort. Nevertheless, the survival rates observed during this time period (1975 to 1989) are not different from those reported in other hospital-based cohort studies [24]. Our study was not designed to identify what intervention led to survival improvements. Nevertheless, several hypotheses could be put forward to explain the improvements in survival observed in our study. The first hypothesis is that advances in surgical resection have led to improvements in survival. The study by Bonenkamp et al [9] was unable to establish significant differences between D1 and D2 resection. However, one explanation would be that the D1 control group had longer than expected survival due to the action of an experienced surgeon. If macroscopically visible lymph nodes were found in the mesenteric region during a surgical intervention, the original objective of which was a D1 resection, we must suppose that the resection proceeded with a wider intervention to include those nodes and therefore became a D2-like dissection.

As in other retrospective analysis [25], our study did not assess which one of these surgical options has changed the outcome of patients. Nevertheless, the predominant use of adjuvant chemotherapy after D2 dissection showed the best results. Post-surgical radiation therapy was not included in the adjuvant treatment of these patients.
Kaplan-Meier survival curves of patients at stages I, II, IIIA and IIIB. Patients with stages II and IIIA treated in 1990 and after had a significantly better long-term survival than those treated before (median survival of >120 months versus 78 months; \( p = 0.0132 \) and >120 months versus 23 months; \( p = 0.0008 \), respectively).

Kaplan-Meier survival curves of patients according to nodal involvement. Significantly better survival was observed among patients treated after 1990, independently of nodal involvement (5-year overall survival of 52% versus 23%; \( p = 0.0001 \) and 73% versus 62%; \( p = 0.0328 \), respectively).
Authors disclosures of potential conflicts of interest
The author(s) declare that they have no competing interest.

Authors' contributions
JGJ designed the study, collected the data and wrote the first draft of the manuscript.
RP, MM, JDD all contributed to collected data and the preparation of the first draft of the manuscript.

MMZ participated in the design of the study and in drafting and revising the manuscript.

JF, OV, CF and JCG all contributed to patient recruitment and revising the manuscript.

All authors read and approved of the manuscript.

Acknowledgements
The authors would like to thank Dr. J.C. Reverter for his guidance in the statistical data analysis of this article.

References
1. Parkin DM, Pisani P, Ferlay J: Estimates of the worldwide incidence of 25 major cancers in 1990. Int J Cancer 1999, 80:827-841.
2. Kelley JR, Duggan JM: Gastric cancer epidemiology and risk factors. J Clin Epidemiol 2003, 56:1-9.
3. Coleman MP, Gatta G, Verdecchia A, Esteve J, Sant M, Storm H, Allemani C, Ciccolollo L, Santagastini M, Berrino F. EUROCARE Working Group: EUROCARE-3 summary: cancer survival in Europe at the end of the 20th century. Ann Oncol 2003, 14(Suppl 5):v128-v149.
4. Sant M, Arealed T, Berrino F, Bielska Lasota M, Carli PM, Faivre J, Grosclaude P, Hedelin G, Matsuda T, Moller H, Moller T, Verdecchia A, Capocaccia R, Gatta G, Micheli A, Santagastini M, Roazzi P, Lisi D, EUROCARE Working Group: EUROCARE-3: survival of cancer patients diagnosed 1990–1994: results and commentary. Ann Oncol 2003, 14(Suppl 5):v61-v118.
5. Hundahl SA, Phillips JL, Menck HR: The National Cancer Data Base report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy. Cancer 2000, 88:921-932.
6. Jemal A, Tiwari RC, Murtia T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ. American Cancer Society: Cancer Statistics, 2004. CA Cancer J Clin 2004, 54:8-29.
7. Dixon E, Vollmer CM Jr, Sahajpal A, Cattral M, Grant D, Doig C, Henning A, Taylor B, Langer B, Greig P, Gallinger S: An aggressive approach leads to improved survival in patients with gallbladder cancer: A 12-year study at a North American Center. Ann Surg 2005, 241:385-394.
8. Cuschieri A, Weeden S, Fielding J, Banczewicz J, Craven J, Joypaul V, Sydes M, Fayers P: Patient survival after D1 and D2 dissections for gastric cancer: Long-term results of the MRC randomised surgical trial. Br J Cancer 1999, 79:1522-1530.
9. Bonenkamp JJ, Hermans J, Sasako M, Van de Velde CJH: Extended lymph node dissection for gastric cancer. N Engl J Med 1999, 340:908-914.
10. McCulloch P: Should general surgeons treat gastric carcinoma? An audit of practice and results, 1980–1985. Br J Surg 1994, 81:417-420.
11. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmerman GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martensen JA: Chemotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001, 345:725-730.
12. Sakamoto J: Adjuvant chemotherapy for gastric cancer in Japan: global and Japanese perspectives. Cancer Chemother Pharmacol 2004, 54(Suppl 1):525-31.

13. Grau JJ, Estape J, Fuster J, Filella X, Visa J, Teres J, Soler G, Albiol S, Garcia-Valdecasas JC, Grande L, et al: Randomized trial of adjuvant chemotherapy with mitomycin C plus fluorouracil versus mitomycin C alone in resected locally advanced gastric cancer. J Clin Oncol 1998, 16:1036-1039.

14. Grau JJ, Domingo-Domenech J, Morente V, Pera M, Garcia-Valdecasas JC, Fuster J, Bombi A, Mellado B, Albanell J, Gascon P: Low thymidylate synthase expression in the primary tumor predicts favorable clinical outcome in resected gastric cancer patients treated with adjuvant tegafur. Oncology 2004, 66:226-233.

15. Kajitani T: Japanese Research Society for the Study of Gastric Cancer.: The general rules for gastric cancer study in surgery and pathology. Jpn J Surg 1981, 11:127-145.

16. American Joint Committee on Cancer: AJCC Cancer Staging Manual. 5th edition. Edited by: Fleming ID, Cooper JS, Henson DE, et al (Eds). Philadelphia. Lippincott-Raven; 1997.

17. Peto R, Pike MC, Armitage P, Breslow NE, Cox DR, Howard SV, Mantel N, McPherson K, Peto J, Smith PG: Design and analysis of randomized clinical trials requiring prolonged observations on each patient. Br J Cancer 1976, 34:585-612.

18. Kaplan EL, Meier P: Nonparametric estimations from incomplete observations. Am Stat Assoc 1958, 53:457-463.

19. Peto R, Pike MC: Conservatism of the approximation $\sigma_0^2-E$ in the logrank test for survival data or tumor incidence data. Biometrics 1973, 29:279-286.

20. Sasaki M, McCulloch P, Kinoshita T, Maruyama K: New method to evaluate the therapeutic value of lymph node dissection for gastric cancer. Br J Surg 1993, 82:346-351.

21. Kikuuchi S, Sakakibara Y, Sakuramoto S, Kobayashi N, Shimao H, Mieno H, Kato Y, Kadowaki K, Hiki Y, Kakita A: Recent results in the surgical treatment of gastric cancer according to the Japanese and TNM classification. Anticancer Res 2001, 21:3589-3594.

22. McCulloch P, Nita M, Kazi H, Gama-Rodrigues J: Extended versus limited nodes dissection technique for adenocarcinoma of the stomach. Cochrane Database Syst Rev 2004:CD001964.

23. Marrelli D, De Stefano A, de Manzoni G, Morgagni P, Di Leo A, Roviello F: Prediction of recurrence after radical surgery for gastric cancer: a scoring system obtained from prospective multicenter study. Ann Surg 2005, 241:247-255.

24. Cunningham D, Allum VH, Stenning SP, Weeden S: Perioperative chemotherapy in operable gastric and lower oesophageal cancer: Final results of a randomised, controlled trial (the MAGIC trial, ISRCTN 93793971). Proc ASCO 2005, Abstr 4001.